Ticker > Company >

Venus Remedies share price

Venus Remedies Ltd.

NSE: VENUSREM BSE: 526953 SECTOR: Pharmaceuticals & Drugs  44.03 K   74   6

468.00
+4.65 (1.00%)
BSE: Today, 04:01 PM

Price Summary

Today's High

₹ 477

Today's Low

₹ 456

52 Week High

₹ 565.95

52 Week Low

₹ 272.2

FinStar

Ownership Below Par
Stock price may face volatility due to ownership structure.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyPoor
The company seems highly inefficient in case of asset management.
FinancialsWeak
Watch out! The company might not be able to sustain any adverse condition.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

625.58 Cr.

Enterprise Value

547.59 Cr.

No. of Shares

1.34 Cr.

P/E

10.46

P/B

1.04

Face Value

₹ 10

Div. Yield

0 %

Book Value (TTM)

₹  449.75

CASH

77.99 Cr.

DEBT

0 Cr.

Promoter Holding

41.76 %

EPS (TTM)

₹  44.75

Sales Growth

11.17%

ROE

9.57 %

ROCE

13.91%

Profit Growth

72.34 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year11.17%
3 Year3.5%
5 Year14.83%

Profit Growth

1 Year72.34%
3 Year2.38%
5 Year53.02%

ROE%

1 Year9.57%
3 Year7.33%
5 Year9.77%

ROCE %

1 Year13.91%
3 Year10.24%
5 Year10.21%

Debt/Equity

0

Price to Cash Flow

7.53

Interest Cover Ratio

0

CFO/PAT (5 Yr. Avg.)

1.48581498845031

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2025 41.76 0.00
Mar 2025 41.76 0.00
Dec 2024 41.76 0.00
Sep 2024 41.76 0.00
Jun 2024 41.76 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has significantly decreased its debt by 38.6789 Cr.
  • Company is virtually debt free.
  • Company’s PEG ratio is 0.144569444683526.
  • The company has an efficient Cash Conversion Cycle of 57.5855 days.
  • Company has a healthy liquidity position with current ratio of 4.1408.
  • The company has a good cash flow management; CFO/PAT stands at 1.48581498845031.
  • The company has a strong degree of Operating leverage, Average Operating leverage stands at 3.30074822291574.

 Limitations

  • The company has shown a poor profit growth of 2.37685292628702% for the Past 3 years.
  • The company has shown a poor revenue growth of 3.5027292382787% for the Past 3 years.
  • Company has a poor ROE of 7.3341% over the past 3 years.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025
Net Sales 105.86 167.02 172.54 194.04 131.85
Total Expenditure 91.58 156.75 149.63 171.49 119.2
Operating Profit 14.28 10.27 22.91 22.55 12.65
Other Income 1.56 10.71 1.74 6.77 8
Interest 0 0 0 0 0
Depreciation 5.76 6.17 5.2 4.49 5.95
Exceptional Items 0 0 9.91 0 0
Profit Before Tax 10.08 14.81 29.36 24.83 14.7
Tax 5.63 5.55 5.28 10.04 3.01
Profit After Tax 4.45 9.26 24.08 14.79 11.69
Adjusted EPS (Rs) 3.33 6.93 18.01 11.06 8.74

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Net Sales 514.62 576.71 537.66 575.21 639.46
Total Expenditure 467.76 507.89 476.14 514.32 569.47
Operating Profit 46.86 68.82 61.53 60.89 70
Other Income 17.76 8.43 10.17 11.32 20.78
Interest 12.73 0 0 0 0
Depreciation 34.28 32.58 31.37 25.55 21.62
Exceptional Items 23.44 0 0 0 9.91
Profit Before Tax 41.06 44.67 40.33 46.65 79.08
Tax -13.21 -4.32 11.36 16.15 26.51
Net Profit 54.27 48.99 28.96 30.5 52.56
Adjusted EPS (Rs.) 43.97 36.65 21.67 22.82 39.32

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity and Liabilities
Share Capital 12.34 13.37 13.37 13.37 13.37
Total Reserves 387.84 436.05 464.68 495.22 576.13
Borrowings 47.52 38.68 38.68 38.68 0
Other N/C liabilities 11.29 7.27 19.49 21.18 18.48
Current liabilities 87.82 82.61 72.67 72.81 105.23
Total Liabilities 546.81 577.98 608.89 641.26 713.21
Assets
Net Block 244.2 224.67 199.68 202.76 214.14
Capital WIP 25.11 25.23 26.1 21.08 26.39
Intangible WIP 0 0 0 0 0
Investments 0.14 0.14 0.14 0.16 0.16
Loans & Advances 62.34 61.96 62.55 51.76 33.56
Other N/C Assets 1.29 1.57 2.23 4.5 3.21
Current Assets 213.74 264.41 318.19 361 435.75
Total Assets 546.81 577.98 608.89 641.26 713.21
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Profit from operations 17.62 44.67 40.33 46.65 69.16
Adjustment 21.59 24.83 22.25 19.36 14.01
Changes in Assets & Liabilities 69.69 -28.5 -34.53 -15.15 14.86
Tax Paid 0 0 0 -15.48 -14.92
Operating Cash Flow 132.34 41 28.05 35.38 83.1
Investing Cash Flow 55.98 -16.75 -50.81 -6.94 -76.2
Financing Cash Flow -161.88 -9.13 0 0 0
Net Cash Flow 26.45 15.12 -22.76 28.44 6.9

Corporate Actions

Investors Details

PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
promoters 41.76 41.76 41.76 41.76 41.76
manu chaudhary 11.73 11.73 11.73 11.73 11.73
pawan chaudhary 12.82 12.82 12.82 12.82 12.82
sunev pharma solutions li... 17.21 17.21 17.21 17.21 17.21
PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
investors 58.24 58.24 58.24 58.24 58.24
acadian emerging markets ... 1.05 1.10 1.10 1.10 1.10
anurag jain - - - 1.12 1.12
investor education and pr... - 1.00 1.00 1.00 1.00
k.b.shekar 1.97 1.97 1.97 1.97 1.94
llp 0.39 0.12 0.20 0.20 0.23
rajni tarun jain - - - 1.50 1.50
pradeep kumar jain 1.87 2.00 2.12 2.78 -
mc jain infoservices priv... 1.50 2.32 2.32 - -
investor education and pr... 1.00 - - - -

Annual Reports

Title Link
Title Link
Annual Report 2021
Annual Report 2019
Annual Report 2018
Annual Report 2017

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
 No Credit reports exist for this company.Report us
TYPE AGENCY Link
TYPE AGENCY Link
 No Research reports exist for this company.Report us

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
 Currently we do not have any Concall related to this company.Report us
TYPE QUARTER Link
TYPE QUARTER Link
 Currently we do not have any Presentation related to this company.Report us

Company News

Venus Remedies - Quaterly Results 1 Aug, 5:00 PM Venus Remedies - Quaterly Results 1 Aug, 5:00 PM Venus Remedies - Quaterly Results 1 Aug, 5:00 PM Venus Remedies informs about confirmation certificate 8 Jul, 12:20 PM Venus Remedies - Quaterly Results 26 May, 10:29 PM Venus Remedies - Quaterly Results 26 May, 10:29 PM Venus Remedies secures Ukrainian GMP renewal 22 May, 2:30 PM USFDA grants QIDP Designation to Venus Remedies’ investigational product VRP-034 17 Apr, 12:59 PM Venus Remedies sings license agreement with lnfex Therapeutics to develop MET-X 25 Feb, 12:43 PM Venus Remedies informs about press release 25 Feb, 10:27 AM Venus Remedies - Quaterly Results 4 Feb, 9:02 PM Venus Remedies - Quaterly Results 4 Feb, 9:02 PM Venus Remedies gets GMP certification for antibiotic-carbapenem facility 31 Dec, 2:45 PM Venus Remedies secures Marketing Authorization in Philippines 6 Dec, 3:51 PM Venus Remedies gets nod to establish wholly owned subsidiary in Hungary 30 Nov, 3:17 PM Venus Remedies informs about press release 5 Nov, 11:37 AM Venus Remedies secures Malaysian PIC/S GMP approval for pre-filled syringe facility 5 Nov, 10:44 AM Venus Remedies - Quaterly Results 29 Oct, 9:59 PM Venus Remedies - Quaterly Results 29 Oct, 9:59 PM Venus Remedies informs about closure of trading window 24 Sep, 5:27 PM Venus Remedies - Quaterly Results 13 Aug, 7:28 PM Venus Remedies informs about postponement of board meeting 17 Jul, 10:16 AM Venus Remedies informs about closure of trading window 26 Jun, 10:05 AM Venus Remedies gets oncology tender from PAHO 19 Jun, 10:50 AM Venus Remedies informs about updates 13 Jun, 12:21 PM Venus Remedies secures award for antibiotic product Ceftriaxone 1gm from UNICEF 13 Jun, 9:50 AM Venus Remedies informs about newspaper publication 1 Jun, 3:03 PM Venus Remedies - Quaterly Results 30 May, 8:54 PM Venus Remedies informs about disclosure 1 Apr, 12:58 PM Venus Remedies gets marketing authorisations from Ukraine for three cancer drugs 18 Mar, 4:47 PM Venus Remedies obtains Marketing Authorizations for range of essential oncology drugs in Ukraine 9 Mar, 3:39 PM Venus Remedies awarded first incentive of Rs 7.50 crore under PLI scheme 6 Mar, 10:30 AM Venus Remedies informs about press release 6 Mar, 9:33 AM Venus Remedies - Quaterly Results 14 Feb, 8:01 PM Venus Remedies - Quaterly Results 14 Feb, 8:01 PM Venus Remedies secures marketing authorizations for Docetaxel, Gemcitabine in Europe 12 Jan, 12:30 PM Venus Remedies secures marketing authorizations for Docetaxel in Israel, Cytarabine in Colombia 21 Dec, 3:13 PM Venus Remedies’ R3SET forays into wellness arena 20 Dec, 2:10 PM Venus Remedies informs about press release 20 Dec, 12:56 PM Venus Remedies informs about disclosure 5 Dec, 12:16 PM Venus Remedies gets market authorizations for Enoxaparin in Azerbaijan 5 Dec, 11:09 AM Venus Remedies informs about press release 1 Dec, 2:06 PM Venus Remedies informs about unaudited financial results 25 Nov, 3:19 PM Venus Remedies informs about press release 6 Nov, 10:23 AM Venus Remedies secures ‘Three Star Export House’ certificate from Government of India 6 Nov, 9:49 AM Venus Remedies informs about press release 1 Nov, 10:45 AM Venus Remedies wins FICCI Healthcare Award 2023 1 Nov, 9:52 AM Venus Remedies achieves market authorization for Bleomycin in United Kingdom 26 Oct, 12:07 PM Venus Remedies informs about press release 26 Oct, 10:38 AM Venus Remedies informs about press release 20 Oct, 11:24 AM

Venus Remedies Stock Price Analysis and Quick Research Report. Is Venus Remedies an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Venus Remedies. 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Venus Remedies has a PE ratio of 10.4609849839113 which is low and comparatively undervalued.

  • Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Venus Remedies has ROA of 7.7615% which is a bad sign for future performance. (Higher values are always desirable.)

  • Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Venus Remedies has a Current ratio of 4.1408.

  • Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Venus Remedies has a ROE of 9.5736%. (Higher is better)

  • Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Venus Remedies has a Debt to Equity ratio of 0 which means that the company has low proportion of debt in its capital.

  • Sales growth: Venus Remedies has reported revenue growth of 11.17% which is poor in relation to its growth and performance. 

  • Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Venus Remedies for the current financial year is 10.9464540364058%.

  • Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Venus Remedies is Rs 0 and the yield is 0%.

  • Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Venus Remedies is Rs 44.752. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Venus Remedies in Ticker for free. Also, one can get the intrinsic value of Venus Remedies by using Valuation Calculators, which are available with a Finology ONE subscription. 

Venus Remedies FAQs

Q1. What is Venus Remedies share price today?
Ans: The current share price of Venus Remedies is Rs 468.15.

Q2. What is the market capitalisation of Venus Remedies?
Ans: Venus Remedies has a market capitalisation of Rs 625.77554322 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Venus Remedies?
Ans: The PE ratio of Venus Remedies is 10.4609849839113 and the P/B ratio of Venus Remedies is 1.04090814594281, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Venus Remedies share?
Ans: The 52-week high share price of Venus Remedies is Rs 567.8, and the 52-week low share price of Venus Remedies is Rs 270.25.

Q5. Does Venus Remedies pay dividends?
Ans: Currently, Venus Remedies does not pay dividends. Dividend yield of Venus Remedies is around 0%.

Q6. What are the face value and book value of Venus Remedies shares?
Ans: The face value of Venus Remedies shares is Rs 10, while the book value per share of Venus Remedies is around Rs 449.7515. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Venus Remedies?
Ans: Venus Remedies has a total debt of Rs 0 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Venus Remedies?
Ans: The ROE of Venus Remedies is 9.5736% and ROCE of Venus Remedies is 13.9123%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Venus Remedies a good buy for the long term?
Ans: The Venus Remedies long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Venus Remedies undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Venus Remedies appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Venus Remedies’s financials?
Ans: You can review Venus Remedies’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.

Last Updated on:
Brief about Venus Remedies
X